[Myoplegia with rocuronium bromide in children].
This study has evaluated the efficacy and safety of different doses of Esmerone in children under fluorothane anesthesia. It enrolled 85 children from a senior age group (7-14 years). According to the myorelaxant used, all the patients were divided into 2 groups: S and R. In the S group (n=25), myoplegia was carried out administering succinylcholine in a dose of 1 mg/kg. In the R group, myorelaxation was achieved using rocuronium bromide (Esmerone). According to the dose used, the group was divided into 3 subgroups, each comprising 20 patients. The initial dose of Esmemrone was 0.3, 0.6, and 0.9 mg/kg, respectively. The efficacy of the agent was evaluated by accelerographic and clinical data. The study has demonstrated that Esmerone was safer than succinylcholine. Increasing the dose (0.3-0.6-0.9 mg/kg) of Esmerone advantages in the onset of NMB and shows an increase in the duration of its action.
Shaginian
A K
AK
Mikhel'son
V A
VA
Agavelian
E G
EG
D000293:Adolescent; D000732:Androstanols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007442:Intubation, Intratracheal; D009126:Muscle Relaxation / Q000187:drug effects*; D019148:Neuromuscular Blockade / Q000379:methods*; D009467:Neuromuscular Depolarizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077123:Rocuronium; D013390:Succinylcholine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000732:Androstanols; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D013390:Succinylcholine; D000077123:Rocuronium